Donor-derived hematopoietic cells in organ transplantation: A major step toward allograft tolerance?

Transplantation

Volumn 75, Issue 9 SUPPL., 2003, Pages

  Rifle, Gerard ^a,b   Mousson, Christiane ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; OKT 4; RAPAMYCIN; SIALIDASE; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; ANIMAL MODEL; BLOOD TRANSFUSION; BONE MARROW CELL; BONE MARROW PURGING; CHIMERA; CONFERENCE PAPER; DENDRITIC CELL; GRAFT SURVIVAL; HEMATOPOIETIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKOCYTE; LYMPHOCYTE DEPLETION; MICROCHIMERISM; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION;

EID: 0037617533     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000067943.90241.73     Document Type: Conference Paper

References (42)

1. Rifle G, Mousson C. Dendritic cells and second signal blockade: A step toward allograft tolerance? Transplantation 2002; 73: S1.
2. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice: VII. Optimal cellular antigen for induction of immunological tolerance with antilymphocyte serum. Transplant Proc 1970; 2: 489.
3. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaver renal allograft recipients. Transplantation 1991; 51: 70.
4. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71: 827.
5. First Beaune Seminar in Transplant Research. Dendritic cells in organ transplantation: Second signal blockade by monoclonal antibodies. Transplantation 2002; 73: S1.
6. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplantation from the same donor. Ann Intern Med 1991; 114: 954.
7. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480.
8. Game DS, Lechler RI. Pathways of allorecognition: Implication for transplantation tolerance. Transpl Immunol 2002; 10: 101.
9. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole organ transplantation; The basis of graft acceptance. Hepatology 1993; 17: 1127.
10. Opelz G, Mickey MR, Sengar DPS, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5: 253.
11. Salvatierra O, Vincenti F, Amend W, et al. Deliberate donor-specific blood transfusions prior to living related renal transplantation: A new approach. Ann Surg 1982; 192: 543.
12. Van Twuyver E, Mooijaart RJD, Ten Berge IJM, et al. Pretransplantation blood transfusion revisited. N Engl J Med 1991; 325: 1210.
13. Roelen D, van Bree S, van Hulst P, et al. Regulatory functions of human CD4 (+) T cells recognizing allopeptides in the context of self-HLA class II. Hum Immunol 2002; 63: 902.
14. Jin T, Toki J, Inaba M, et al. A novel strategy for organ allografts using sublethal (7 Gy) irradiation followed by injection of donor bone marrow cells via portal vein. Transplantation 2001; 71: 1725.
15. Neipp M, Gammie JS, Exner BG, et al. A partial conditioning approach to achieve mixed chimerism in the rat: Depletion of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment. Transplantation 1999; 68: 369.
16. Colson YL, Li H, Boggs SS, et al. Durable mixed allogenic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820.
17. Higuchi M, Zeng D, Shizuru J, et al. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J Immunol 2002; 169: 5564.
18. Mapara MY, Pelot M, Zhao G, et al. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant 2001; 7: 646.
19. Shirasugi N, Adams AB, Durham MM, et al. Prevention of chronic rejection in murine cardiac allografts: A comparison of chimerism and non-chimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169: 2677.
20. de Vries-van der Zwan A, Besseling AC, de Waal LP, et al. Specific tolerance induction and transplantation: A single-day protocol. Blood 1997; 89: 2596.
21. Bingaman AW, Waitze SY, Alexander DZ, et al. Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning. Transplantation 2000; 69: 2491.
22. Nagahama T, Sugiura K, Lee S, et al. A new method for tolerance induction: Busulfan administration followed by intravenous injection of neuraminidase-treated bone marrow. Stem Cells 2001; 19: 425.
23. Ikebukuro K, Adachi Y, Yamada Y, et al. Treatment of streptozotocin-induced diabetes mellitus by transplantation of islets cells plus bone marrow cells via portal vein in rats. Transplantation 2002; 73: 512.
24. Hale DA, Gottschalk R, Umemura A, et al. Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation: A unique role for sirolimus. Transplantation 2000; 69: 1242.
25. Pearson TC, Madsen JC, Larsen CP, et al. Induction of transplantation tolerance using donor antigen and anti-CD4 monoclonal antibody. Transplantation 1992; 54: 475.
26. Pearson TC, Alexander DZ, Hendrix R, et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model: Evidence for hematopoietic chimerism. Transplantation 1996; 61: 997.
27. Parker DC, Greiner DL, Philips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogenic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560.
28. Wekerle T, Kurtz J, Ito H, et al. Allogenic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464.
29. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1.
30. Schwarze ML, Menard MT, Fuchimoto Y, et al. Mixed hematopoietic chimerism induces long-term tolerance to cardiac allografts in miniature swine. Ann Thorac Surg 2000; 70: 131.
31. Kawai T, Cosimi AB, Wee SL, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 2002; 73: 1757.
32. Morelli AE, Hackstein H, Thomson AW. Potential of tolerogenic dendritic cells for transplantation. Semin Immunol 2001; 13: 323.
33. + bone marrow cells in cadaver kidney transplantation. Nephrol Dial Transplant 1998; 1: 34.
34. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitors transplantation. Transplantation 2002; 73: 1386.
35. Gur H, Krauthgamer R, Bemmebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells: Expansion of veto cells by short term culture of purified human CD 34 (+) cells. Blood 2002; 99: 4174.
36. Hirano A, Luke PP, Specht SM, et al. Graft hyporeactivity induced by immature donor-derived dendritic cells. Transpl Immunol 2000; 8: 161.
37. Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40L pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997; 64: 1808.
38. Lutz M, Schuler G. Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Immunol 2002; 23: 445.
39. Simoneau-Robin I, Mousson C, Zanetta G, et al. In vitro study of alloreactivity and microchimerism after injection of dendritic cells and anti-CD4 monoclonal antibody in a combination of Lewis-Wistar Furth rats. Transplant Proc 1998; 30: 2857.
40. O'Connell PJ, Li W, Wang Z, et al. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol 2002; 168: 143.
41. Niimi M, Shirasugi N, Ikeda Y, et al. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway. Transplantation 2001; 72: 1556.
42. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002; 73: S19.